Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Partners with CRUK to Validate miRNA Marker for Colorectal Cancer Drug Response

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it is collaborating with Cancer Research UK to validate a microRNA as a biomarker for the prediction of progression-free survival in patients with metastatic colorectal cancer who have received anti-EGFR therapy.

According to the company, recent data from researchers at the French Institute of Health and Medical Research show that expression of the miRNA, called miR-31-3p, in primary tumor samples is associated with anti-EGFR response in KRAS wild-type patients with the disease who have been treated with EGFR inhibitors.

In collaboration with researchers from Cancer Research UK, who have investigated the use of anti-EGFR antibodies in KRAS wild-type patients with colorectal cancer, IntegraGen will further investigate the expression of miR-31-3p in both primary and metastatic tumors to determine its ability to predict patient outcomes.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.